Rodina Vatanparast, M.D.
2022, American Board of Internal Medicine, Hematology
2021, American Board of Internal Medicine, Oncology
2018, American Board of Internal Medicine, Internal Medicine
2000-2004, M.D., St. George's University School of Medicine, St. George's, Grenada
1993-1997, B.A., Molecular, Cellular, and Developmental Biology, University of California, Santa Cruz Santa Cruz, California
2008-2011, Fellow, Drexel University College of Medicine/Hahnemann University Hospital, Department of Hematology and Oncology, Philadelphia, PA
2007-2008, Chief Medical Resident, Department of Internal Medicine, Drexel University College of Medicine/Hahnemann University Hospital, Philadelphia, PA
2004-2007, Internal Medicine Residency, Drexel University College of Medicine/Hahnemann University Hospital, Philadelphia, PA
2021-present, Medical Oncologist and Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Torrance, CA
2020-2021, Physician, PIH Health, Division Hematology/Oncology, Downey CA
2013-2020, Physician, The Oncology Institute of Hope and Innovation, Downey, CA
2011-2013, Physician, Comprehensive Cancer & Hematology Specialists, P.C., Voorhees, NJ
1998-2000, Assistant Laboratory Manager/Research Associate, IMPATH/BIS Laboratories, Los Angeles, CA
1996-1997, Research Associate, Santa Cruz Biotechnology, Santa Cruz, CA
2019, Super Doctors Los Angeles
2018, Super Doctors Los Angeles
2016, Super Doctors Los Angeles
2020-present, Judicial Review Committee, PIH Health, Downey, CA
2014-present, Medical Policy Committee, PIH Health, Downey, CA
2014-present, Peer Review Committee, PIH Health, Downey, CA
2019-2020, Director of Utilization Management, The Oncology Institute of Hope and Innovation, Downey, CA
2019-2020, Physician Oversight Supervisor, Pharmacy, The Oncology Institute of Hope and Innovation, Downey, CA
2016-2018, Chair, Interdisciplinary Committee, PIH Health, Downey, CA
2016-2018, Chair, Credentials Committee, PIH Health, Downey, CA
2016-2018, Member, Medical Executive Committee, PIH Health, Downey, CA
2012-2013, Kennedy University Hospital Cancer Committee, Performance Improvement Coordinator, Washington Township, NJ
2011-2013, Virtua Health System Breast Leadership Panel, Voorhees, NJ
2008, Drexel University College of Medicine CME Assistant Program Director, Quality Improvement Conference, Department of Medicine, Philadelphia, PA
2007-2008, Hahnemann University Hospital Performance Improvement Council Member, Philadelphia, PA
2007-2008, Hahnemann University Hospital Medical Records Committee, Member, Philadelphia, PA
2004-2008, Drexel University College of Medicine/Hahnemann University Hospital Resident Education Committee, Member, Philadelphia, PA
2004-2008, Drexel University College of Medicine/Hahnemann University Hospital Resident Recruitment Committee, Member, Philadelphia, PA
- Vatanparast R, Pillai P, Crane G, Minter S, Ward K, Topolsky D, Styler M, Crilley PA. Evaluation of the Pre-Test Scoring System (4Ts) for the Evaluation and Management of Heparin Induced Thrombocytopenia. Blood. Journal of the American Society of Hematology. Volume 116, Nov 2010. Abstract 2551.
- Pillai P, Ranganathan R, Vatanparast R, Lantz S, Bachegowda L, Styler M1, Topolsky D, Ann Crilley PA. Validation of the European Practice Guidelines for the Use of Recombinant Activated Factor VII In Patients with Massive Bleeding. Blood. Journal of the American Society of Hematology, Volume 116. November 2010. Abstract 4744.
- Umiel T, Vatanparast R, Prilutskaya M, Barken I, Moss TJ. Tumor Enriched Immunocytochemical Assay for the Detection of Circulating Breast and Prostate Cancer Cells in Patient's Peripheral Blood. American Society of Clinical Oncology. 2000. Abstract #2629.
- Moss TJ, Umiel T, Vatanparast R, Lazarus HM. Detection of CD20+ Lymphoma Cells in Peripheral Blood Stem Cell Products Using Immunocytochemical and Clonogenic Assays. Blood. Journal of the American Society of Hematology, Volume 94, November 1999.
- Umiel T, Joyce R, Vatanparast R, Moss TJ. Tumor Enriched Immunocytochemical Assay for the Detection of Breast Cancer Cells in Patient Peripheral Blood Stem Cell (PBSC) Products. Blood. Journal of the American Society of Hematology. Volume 94, November 1999.